Business
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fourth quarter; Access for 275,000 total patients across customer base expected by year-end Vadadustat post-hoc data analysis presented at ASN Kidney Week demonstrates composite of all-cause mortality and hospitalization outcomes statistically more favorable for patients receiving vadadustat compared to ES
About this update from Davita Inc.
[{"type":"image","alt":"Akebia Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Akebia Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/865d2292021f9ae78a76043efeea8849"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_bsAI2TGvJhraBA7ZLgS7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/865d2292021f9ae78a76043efeea8849","width":300,"height":122}},"lazy":false},{"type":"text","content":"Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million","length":131,"tagName":"p"},{"type":"text","content":"Operational pilot of Vafseo at DaVita expected to complete in the fourth quarter; Access for 275,000 total patients across customer base expected by year-end ","length":157,"tagName":"p"},{"type":"text","content":"Vadadustat post-hoc data analysis presented at ASN Kidney Week demonstrates composite of all-cause mortality and hospitalization outcomes statistically more favorable for patients receiving vadadustat compared to ESAs ","length":217,"tagName":"p"},{"type":"text","content":"Akebia to host Conference Call at 8:00 a.m. ET on Monday, November 10, 2025","length":75,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2025 and recent business highlights.","length":309,"tagName":"p"},{"type":"text","content":"“Through the quarter we’ve continued to make progress against our goal to make Vafseo standard of care for the treatment of anemia for patients on dialysis and capitalize on nephrologists’ strong desire to prescribe Vafseo,” said John P. Butler, Chief Executive Officer of Akebia. “These efforts include generating incremental data, like the data Dr. Glenn Chertow presented last week at ASN Kidney Week, further informing physicians about potential additional benefits of the product, and enabling increased patient access to Vafseo. To that end, we expect to close the year with four times the prescribing access to Vafseo as compared to the end of Q3, whi...